Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
J Neurochem ; 109(3): 733-43, 2009 May.
Artículo en Inglés | MEDLINE | ID: mdl-19222702

RESUMEN

The combination of bone morphogenetic protein 7 (BMP7) and neurotrophins (e.g. brain-derived neurotrophic factor, BDNF) protects septal neurons during hypoglycemic stress. We investigated the signaling mechanisms underlying this synergistic protection. BMP7 (5 nM) increased phosphorylation and nuclear translocation of BMP-responsive Smads 1/5/8 within 30 min in cultures of rat embryonic septal neurons. BDNF (100 ng/mL) enhanced the BMP7-induced increase in phospho-Smad levels in both nucleus and cytoplasm; this effect was more pronounced after a hypoglycemic stress. BDNF increased both Akt and Erk phosphorylation, but pharmacological blockade of these kinase pathways (with wortmannin and U0126, respectively) did not reduce the Smad phosphorylation produced by the BMP7 + BDNF combination. Inhibitors of casein kinase II (CK2) activity reduced the (BMP7 + BDNF)-induced Smad phosphorylation, and this trophic factor combination increased CK2 activity in hypoglycemic cultures. These findings suggest that BDNF can increase BMP-dependent Smad phosphorylation via a mechanism requiring CK2.


Asunto(s)
Proteína Morfogenética Ósea 7/farmacología , Factor Neurotrófico Derivado del Encéfalo/farmacología , Quinasa de la Caseína II/metabolismo , Hipoglucemia/prevención & control , Neuronas/efectos de los fármacos , Tabique del Cerebro/citología , Estrés Fisiológico/efectos de los fármacos , Proteínas Nucleares snRNP/metabolismo , Animales , Quinasa de la Caseína II/antagonistas & inhibidores , Células Cultivadas , Relación Dosis-Respuesta a Droga , Sinergismo Farmacológico , Embrión de Mamíferos , Inhibidores Enzimáticos/farmacología , Glucosa , Hipoglucemia/inducido químicamente , Hipoglucemia/metabolismo , Neuronas/metabolismo , Fosforilación/efectos de los fármacos , Poli(ADP-Ribosa) Polimerasas/metabolismo , Transporte de Proteínas/efectos de los fármacos , Ratas , Análisis de Regresión , Transducción de Señal/efectos de los fármacos , Transducción de Señal/fisiología , Proteína de Unión a TATA-Box/metabolismo , Factores de Tiempo
2.
J Comp Neurol ; 523(2): 197-208, 2015 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-25185516

RESUMEN

The new mutant mouse shaking (shk) differs from other "myelin mutants" in having a more stable neurological impairment and a much longer lifespan. We have shown that transverse bands (TBs), the component of the paranodal junction (PNJ) that attaches the myelin sheath to the axon, are present in the shk central nervous system (CNS), in contrast to more severely affected mutants, in which TBs are absent or rare. We have proposed that TBs are the major determinant underlying shk neurological stability and longevity. Here we report that TBs are abundant not only in the shk CNS but also in its peripheral nervous system (PNS), which, as in other "myelin mutants", is not as severely dysmyelinated as the CNS but does display structural abnormalities likely to affect impulse propagation. In particular, myelin sheaths are thinner than normal, and some axonal segments lack myelin sheaths entirely. In addition, we establish that the shk mutation, previously localized to chromosome 17, is a quaking (qk) allele consisting of a 105-nucleotide insertion in the qk regulatory region that decreases qk transcription but does not extend to the Parkin and Parkin coregulated genes, which are affected in the qk allele. We conclude that: 1) dysmyelination is less severe in the shk PNS than in the CNS, but TBs, which are present in both locations, stabilize the PNJs and prevent the progressive neurological deficits seen in mutants lacking TBs; and 2) the insertional mutation in shk mice is sufficient to produce the characteristic neurological phenotype without involvement of the Parkin and Parkin coregulated genes.


Asunto(s)
Enfermedades Desmielinizantes/genética , Enfermedades Desmielinizantes/patología , Vaina de Mielina/patología , Proteínas de Unión al ARN/genética , Alelos , Animales , Axones/patología , Axones/fisiología , Encéfalo/patología , Enfermedades Desmielinizantes/fisiopatología , Femenino , Masculino , Ratones de la Cepa 129 , Ratones Endogámicos C57BL , Ratones Mutantes , Mutagénesis Insercional , Vaina de Mielina/fisiología , Conducción Nerviosa , Nervio Óptico/patología , Fenotipo , Proteínas de Unión al ARN/metabolismo , Nervio Ciático/patología , Nervio Ciático/fisiopatología , Médula Espinal/patología , Médula Espinal/fisiopatología
3.
OMICS ; 19(8): 435-42, 2015 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-26161545

RESUMEN

Diagnostics spanning a wide range of new biotechnologies, including proteomics, metabolomics, and nanotechnology, are emerging as companion tests to innovative medicines. In this Opinion, we present the rationale for promulgating an "Essential Diagnostics List." Additionally, we explain the ways in which adopting a vision for "Health in All Policies" could link essential diagnostics with robust and timely societal outcomes such as sustainable development, human rights, gender parity, and alleviation of poverty. We do so in three ways. First, we propose the need for a new, "see through" taxonomy for knowledge-based innovation as we transition from the material industries (e.g., textiles, plastic, cement, glass) dominant in the 20(th) century to the anticipated knowledge industry of the 21st century. If knowledge is the currency of the present century, then it is sensible to adopt an approach that thoroughly examines scientific knowledge, starting with the production aims, methods, quality, distribution, access, and the ends it purports to serve. Second, we explain that this knowledge trajectory focus on innovation is crucial and applicable across all sectors, including public, private, or public-private partnerships, as it underscores the fact that scientific knowledge is a co-product of technology, human values, and social systems. By making the value systems embedded in scientific design and knowledge co-production transparent, we all stand to benefit from sustainable and transparent science. Third, we appeal to the global health community to consider the necessary qualities of good governance for 21st century organizations that will embark on developing essential diagnostics. These have importance not only for science and knowledge-based innovation, but also for the ways in which we can build open, healthy, and peaceful civil societies today and for future generations.


Asunto(s)
Salud Global/ética , Técnicas de Diagnóstico Molecular/tendencias , Innovación Organizacional , Salud Pública/ética , Biomarcadores/análisis , Servicios de Diagnóstico/economía , Servicios de Diagnóstico/ética , Servicios de Diagnóstico/provisión & distribución , Salud Global/economía , Salud Global/tendencias , Conocimientos, Actitudes y Práctica en Salud , Humanos , Farmacogenética/educación , Salud Pública/economía , Salud Pública/tendencias
4.
Int J Dev Neurosci ; 29(3): 259-81, 2011 May.
Artículo en Inglés | MEDLINE | ID: mdl-20920576

RESUMEN

Over the last fifteen years it has become established that 22q11.2 deletion syndrome (22q11DS) is a true genetic risk factor for schizophrenia. Carriers of deletions in chromosome 22q11.2 develop schizophrenia at rate of 25-30% and such deletions account for as many as 1-2% of cases of sporadic schizophrenia in the general population. Access to a relatively homogeneous population of individuals that suffer from schizophrenia as the result of a shared etiological factor and the potential to generate etiologically valid mouse models provides an immense opportunity to better understand the pathobiology of this disease. In this review we survey the clinical literature associated with the 22q11.2 microdeletions with a focus on neuroanatomical changes. Then, we highlight results from work modeling this structural mutation in animals. The key biological pathways disrupted by the mutation are discussed and how these changes impact the structure and function of neural circuits is described.


Asunto(s)
Deleción Cromosómica , Cromosomas Humanos Par 22/genética , Predisposición Genética a la Enfermedad , Trastornos Mentales/genética , Trastornos Mentales/patología , Animales , Encéfalo/anomalías , Encéfalo/fisiología , Encéfalo/fisiopatología , Catecol O-Metiltransferasa/genética , Catecol O-Metiltransferasa/metabolismo , Modelos Animales de Enfermedad , Epistasis Genética , Humanos , Células Madre Pluripotentes Inducidas/fisiología , MicroARNs/metabolismo , Modelos Genéticos , Prolina Oxidasa/genética , Prolina Oxidasa/metabolismo , Esquizofrenia/genética , Síndrome
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA